皮下托珠单抗治疗的类风湿关节炎患者停用甲氨蝶呤后的持续应答:随机对照试验结果
本研究纳入718例对甲氨蝶呤应答不足的类风湿关节炎患者,接受甲氨蝶呤联合皮下托珠单抗162 mg治疗,24周时达DAS28-ESR≤3.2者随机分为托珠单抗单药组(n=147)或继续联合甲氨蝶呤组(n=147)至52周。主要终点为24周至40周DAS28-ESR平均变化,单药组0.46 vs 联合组0.14(加权差值0.318,95%CI 0.045, 0.592),停用甲氨蝶呤非劣于继续使用;两组安全性事件大致相似,最常见严重不良事件为感染(单药组2.1% vs 联合组2.2%)。
要点
- 托珠单抗联合甲氨蝶呤达低疾病活动度后停用甲氨蝶呤,16周内疾病活动度未显著恶化。
- 24周至40周DAS28-ESR平均变化单药组0.46 vs 联合组0.14,加权差值0.318(95%CI 0.045, 0.592)。
- 最常见严重不良事件为感染,单药组2.1% vs 联合组2.2%。
核心结论
- 接受托珠单抗联合甲氨蝶呤治疗并达低疾病活动度的类风湿关节炎患者,停用甲氨蝶呤后16周内疾病活动度未显著恶化。
研究设计与样本
- 随机对照试验,纳入718例对甲氨蝶呤应答不足的类风湿关节炎患者,先接受甲氨蝶呤联合皮下托珠单抗162 mg治疗。
- 24周时DAS28-ESR≤3.2的患者随机分为托珠单抗单药组(n=147)或继续联合甲氨蝶呤组(n=147)至52周。
- 主要终点为24周至40周DAS28-ESR平均变化,非劣效界值0.6。
主要发现
- 24周至40周DAS28-ESR平均变化:托珠单抗单药组0.46 vs 联合甲氨蝶呤组0.14,加权差值0.318(95%CI 0.045, 0.592)。
- 停用甲氨蝶呤在托珠单抗应答者中非劣于继续使用甲氨蝶呤。
- 随机治疗组间安全性事件大致相似;最常见严重不良事件为感染,托珠单抗单药组2.1% vs 联合甲氨蝶呤组2.2%。
关键数值与推荐
- 主要终点非劣效界值为0.6。
- 24周至40周DAS28-ESR平均变化加权差值0.318(95%CI 0.045, 0.592)。
- 严重不良事件感染发生率:托珠单抗单药组2.1% vs 联合甲氨蝶呤组2.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether tocilizumab (TCZ) monotherapy is noninferior to treatment with TCZ plus methotrexate (MTX) for maintaining clinical responses in patients with rheumatoid arthritis (RA) in whom low disease activity is achieved with TCZ plus MTX. METHODS: Patients with RA who experienced an inadequate response to MTX received MTX plus TCZ 162 mg subcutaneously. At 24 weeks, patients who achieved a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) of ≤3.2 were randomized to receive TCZ monotherapy or to continue treatment with TCZ plus MTX until week 52. The primary outcome measure was the comparison of the mean change in the DAS28-ESR from week 24 to week 40 between the TCZ monotherapy and TCZ plus MTX arms (noninferiority margin of 0.6). Secondary outcome measures included worsening of the DAS28-ESR by ≥1.2, achievement of a DAS28-ESR of <2.6 and ≤3.2, and safety and immunogenicity. RESULTS: Among the 718 patients enrolled, 296 were randomized at week 24 to receive TCZ monotherapy (n = 147) or TCZ plus MTX (n = 147). The mean changes in the DAS28-ESR from week 24 to week 40 were 0.46 and 0.14 in the TCZ monotherapy arm and the TCZ plus MTX arm, respectively (weighted difference between the groups, 0.318 [95% confidence interval 0.045, 0.592]); discontinuing MTX in TCZ responders was noninferior to continuing MTX. Safety events were broadly similar between the randomized treatment groups; the most common serious adverse event was infection, which occurred in 2.1% of patients in the TCZ monotherapy group and 2.2% of patients receiving TCZ plus MTX. CONCLUSION: Patients with RA receiving TCZ plus MTX who achieve low disease activity can discontinue MTX without significant worsening of disease activity during the 16 weeks following MTX discontinuation.
引用
- Kremer JM, Rigby W, Singer NG, et al. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial. Arthritis Rheumatol. 2018. PMID: 29575803. doi:10.1002/art.40493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。